Clinical Trial Update: 177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Lutetium-177 dotatate treatment prediction using multimodality imaging in refractory gastroenteropancreatic neuroendocrine tumors has c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroenteropancreatic Neuroendocrine Tumors

Drugs mentioned

• 177Lu-octreotate (Lutetium-177 dotatate)

Snippet

Sponsor: Jules Bordet Institute | Conditions: Gastroenteropancreatic Neuroendocrine Tumors | Phase 3 | Status: COMPLETED